New Colon Cancer Test Might Spot Troub...(individuals who had undergone colonoscop...),Health

Only about 20 percent of results were false positives, while only 9 percent of cancers went undetected.

There was also a correlation between the level of CCSA-2 in the blood and the size of the growth. The highest levels of CCSA-2 indicated the presence of actual cancer. The study was funded by Onconome, which has licensed the patent for the test from the University of Pittsburgh researchers.

The second study, conducted by the American Cancer Society, found that patients without health insurance were almost two times more likely and Medicaid patients 40 percent more likely to be diagnosed with stage II colon cancer rather than stage I disease, compared to those with Medicare or private insurance.

And again, uninsured patients were twice as likely while Medicaid patients were 50 percent more likely to be diagnosed with stage III or IV colon cancer than patients in the other insurance categories. The results held steady no matter where the cancer was found.

Minorities, females, older patients, those who lived in areas with low-income and low-education levels and those who were treated at non-research teaching hospitals were more likely to be diagnosed with advanced cancer.

"Improved access to screening and medical care in these populations may be able to reduce these disparities," said study author Dr. Michael Halpern, strategic director of health services research at the American Cancer Society.

And the third study confirmed that only patients who have a normal form of the KRAS gene in their tumors will benefit from the monoclonal antibody Vectibix (panitumumab). Mutations are found in 30 percent to 50 percent of colorectal cancer patients. The study was funded by Amgen, which makes the drug.

More information

Visit '/>"/>